Intercept Pharmaceuticals Inc (NASDAQ:ICPT) insider Lisa Bright sold 5,000 shares of the business’s stock in a transaction dated Tuesday, December 4th. The stock was sold at an average price of $111.42, for a total transaction of $557,100.00. Following the completion of the transaction, the insider now directly owns 22,488 shares in the company, valued at $2,505,612.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

NASDAQ ICPT opened at $102.26 on Friday. Intercept Pharmaceuticals Inc has a 52 week low of $51.05 and a 52 week high of $133.74. The company has a current ratio of 5.98, a quick ratio of 5.98 and a debt-to-equity ratio of 3.83.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Wednesday, October 31st. The biopharmaceutical company reported ($2.18) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.65) by $0.47. The business had revenue of $47.00 million for the quarter, compared to the consensus estimate of $48.24 million. Intercept Pharmaceuticals had a negative net margin of 202.93% and a negative return on equity of 645.54%. The company’s revenue was up 13.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($2.89) earnings per share. Equities analysts expect that Intercept Pharmaceuticals Inc will post -10.35 earnings per share for the current fiscal year.

A number of equities analysts recently weighed in on ICPT shares. Zacks Investment Research raised shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $113.00 price target on the stock in a report on Tuesday, November 13th. Wedbush set a $220.00 price target on shares of Intercept Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, November 6th. Cantor Fitzgerald reissued an “overweight” rating and issued a $170.00 price target on shares of Intercept Pharmaceuticals in a report on Monday, October 1st. Roth Capital started coverage on shares of Intercept Pharmaceuticals in a report on Wednesday, September 12th. They issued a “buy” rating and a $192.00 price target on the stock. Finally, BidaskClub raised shares of Intercept Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 2nd. Seven analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Intercept Pharmaceuticals currently has an average rating of “Buy” and an average price target of $148.25.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State of Wisconsin Investment Board lifted its holdings in Intercept Pharmaceuticals by 95.9% during the second quarter. State of Wisconsin Investment Board now owns 22,700 shares of the biopharmaceutical company’s stock valued at $1,905,000 after purchasing an additional 11,111 shares during the last quarter. FMR LLC lifted its holdings in Intercept Pharmaceuticals by 17.5% during the second quarter. FMR LLC now owns 4,437,332 shares of the biopharmaceutical company’s stock valued at $372,336,000 after purchasing an additional 661,542 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in Intercept Pharmaceuticals by 104.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 110,805 shares of the biopharmaceutical company’s stock valued at $9,298,000 after purchasing an additional 56,556 shares during the last quarter. Asymmetry Capital Management L.P. purchased a new stake in Intercept Pharmaceuticals during the second quarter valued at about $2,175,000. Finally, Rhumbline Advisers lifted its holdings in Intercept Pharmaceuticals by 11.5% during the second quarter. Rhumbline Advisers now owns 21,153 shares of the biopharmaceutical company’s stock valued at $1,775,000 after purchasing an additional 2,181 shares during the last quarter. 63.62% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This report was reported by Daily Political and is owned by of Daily Political. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2018/12/08/insider-selling-intercept-pharmaceuticals-inc-icpt-insider-sells-5000-shares-of-stock.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).

See Also: What is a balanced fund?

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.